Comparative antipseudomonal activity of some newer beta-lactam agents.
AUTOR(ES)
Greenwood, D
RESUMO
The antipseudomonal activities of cefotaxime, ceftizoxime, ceftazidime, ceftriaxone, cefoperazone, and moxalactam were tested in conventional minimum inhibitory concentration titrations and according to morphological and turbidimetric criteria. Three groups of pseudomonal strains were tested: carbenicillin hypersusceptible, carbenicillin susceptible, and carbenicillin resistant. In minimum inhibitory concentration titrations, the carbenicillin-hypersusceptible strains did not differ greatly in their susceptibility to other beta-lactam agents, although moxalactam appeared to be rather less active than the other drugs. When tested against the remaining strains, ceftazidime was the most active compound, followed by cefoperazone and ceftriaxone. The turbidimetric experiments supported by microscopical observations, all of the agents induced bacterial lysis in the carbenicillin-hypersusceptible strains, but cefoperazone appeared to be less actively bacteriolytic than the rest of the antibiotics. None of the agents was able to prevent growth of the remainder of the Pseudomonas aeruginosa strains in the first few hours of drug exposure, during which time the bacteria elongated to form long filaments. However, the various agents differed in the length of time which elapsed before growth was completely halted. Judged in this way, moxalactam was the most active compound in relation to its minimum inhibitory concentration, but in comparative experiments in which the same concentration of each drug (64 microgram/ml) was used regardless of the minimum inhibitory concentration, ceftazidime appeared to be the most active antibiotic, followed by ceftriaxone and cefotaxime.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=181860Documentos Relacionados
- Interactions of beta-lactam antibiotics and antineoplastic agents.
- Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.
- Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.
- Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents.
- In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.